object
neopterin
gener
releas
increas
amount
macrophag
upon
activ
interferong
immun
respons
potenti
use
neopterin
earli
prognost
inform
dengu
viru
infect
investig
method
neopterin
concentr
determin
serum
sampl
dengu
fever
df
patient
neopterin
level
compar
measl
influenza
patient
healthi
blood
donor
serv
control
result
acut
sera
df
patient
mean
neopterin
concentr
nmol
l
higher
patient
measl
mean
nmoll
influenza
nmoll
healthi
control
nmoll
p
correspond
author
tel
fax
patient
confirm
df
earli
neopterin
elev
detect
alreadi
first
day
onset
symptom
rose
maximum
level
nmoll
day
onset
higher
increas
neopterin
level
df
patient
associ
longer
durat
fever
thu
predict
clinic
cours
diseas
conclus
neopterin
concentr
found
significantli
higher
df
patient
compar
healthi
control
also
viral
infect
p
may
allow
earli
assess
sever
df
british
infect
societi
publish
elsevi
ltd
right
reserv
dengu
acut
febril
diseas
result
infect
dengu
viru
group
four
antigen
relat
flavivirus
design
serotyp
transmiss
involv
ingest
virem
blood
mosquito
subsequ
passag
suscept
human
host
princip
vector
aed
aegypti
dengu
viru
infect
manifest
dengu
fever
df
uncompl
febril
ill
dengu
hemorrhag
feverdengu
shock
syndrom
dhfdss
sever
form
consider
evid
suggest
abnorm
immun
respons
disturb
immun
regul
basi
pathogenesi
macrophag
import
target
dengu
viru
infect
known
produc
variou
cytokin
upon
stimul
dengu
viru
infect
cytokin
may
releas
either
directli
virusinfect
cell
monocyt
macrophag
upon
interact
virusinfect
cell
immunocompet
cell
activ
lymphocyt
immun
respons
eg
trigger
viral
infect
molecular
weight
da
gener
releas
increas
amount
human
macrophag
upon
activ
cytokin
interferong
accordingli
determin
neopterin
concentr
bodi
fluid
use
monitor
cellular
immun
activ
variou
diseas
infect
autoimmun
diseas
malign
disord
earli
detect
allograft
reject
episod
particular
increas
neopterin
concentr
blood
urin
earli
sensit
indic
presenc
broad
panel
viral
infecti
diseas
includ
human
immunodefici
viru
type
degre
neopterin
elev
eg
patient
infect
predict
valu
acut
infect
cytomegaloviru
rubella
increas
neopterin
concentr
observ
specif
antibodi
becam
detect
howev
increas
neopterin
concentr
specif
viru
infect
neopterin
level
earli
stage
df
patient
may
sensit
indic
estim
sever
diseas
date
one
small
studi
import
neopterin
dengueinfect
patient
avail
scientif
literatur
show
correl
sever
ill
neopterin
level
ie
highest
level
dhfdss
howev
sampl
size
small
draw
persuas
conclus
present
studi
detect
concentr
neopterin
serum
sampl
collect
df
patient
confirm
serolog
andor
virolog
sera
healthi
blood
donor
sampl
also
test
patient
confirm
influenza
viru
infect
measl
viru
infect
two
common
diseas
fever
similar
earli
symptom
viral
infecti
diseas
control
studi
df
patient
admit
hospit
guangzhou
august
novemb
contact
histori
live
around
known
df
patient
travel
histori
high
fever
c
least
day
df
patient
show
elev
igm
antibodi
without
detect
igg
antibodi
dengu
viru
accord
criteria
diagnosi
df
patient
also
confirm
virolog
test
viru
isol
andor
pcr
df
patient
identifi
infect
serotyp
dengu
viru
serolog
andor
virolog
test
clinic
inform
df
patient
summar
tabl
pair
sera
taken
df
patient
singl
sera
taken
df
patient
total
serum
sampl
df
patient
collect
antibodi
neopterin
detect
studi
onehundr
fifti
acut
sera
collect
within
day
ae
day
mean
ae
sd
onset
diseas
serum
sampl
also
collect
measl
patient
male
femal
averag
age
ae
year
mean
ae
sd
rang
year
influenza
patient
male
femal
averag
age
ae
year
mean
ae
sd
rang
year
confirm
accord
china
health
ministri
standard
clinic
laboratori
hospit
viral
infecti
diseas
control
measl
sampl
collect
within
day
ae
day
mean
ae
sd
onset
diseas
influenza
sampl
also
collect
within
day
ae
day
mean
ae
sd
onset
diseas
serum
sampl
noninfecti
control
obtain
healthi
adult
male
femal
averag
age
ae
year
mean
ae
sd
rang
year
blood
bank
red
cross
hong
kong
sera
guangzhou
sera
control
serum
sampl
store
c
use
patient
inform
consent
part
blood
specimen
obtain
routin
procedur
anonym
refer
addit
analys
within
studi
presenc
dengu
viru
detect
isol
viru
sampl
andor
viral
rna
rtepcr
viru
isol
cell
gener
gift
institut
viral
diseas
control
prevent
china
cdc
serotyp
isol
viru
identifi
immun
fluoresc
assay
ifa
use
specif
ieiv
monoclon
antibodi
chemicon
co
ltd
usa
viral
rna
also
test
rtepcr
directli
specimen
briefli
viral
rna
extract
sampl
use
rneasi
mini
kit
qiagen
chatsworth
ca
usa
firststrand
cdna
synthes
use
rna
revers
transcriptas
life
technolog
inc
md
usa
random
primer
subsequ
pcr
carri
use
pcr
kit
invitrogen
corp
ca
usa
pair
primer
determin
presenc
viru
serotyp
viru
posit
sampl
identifi
use
seri
primer
dengu
viru
specif
antibodi
igm
igg
test
dengu
blot
kit
genelab
co
ltd
singapor
elisa
kit
ibl
co
ltd
germani
accord
instruct
compani
method
describ
previous
neopterin
assay
serum
neopterin
determin
use
commerci
avail
elisa
elitest
neopterinscreen
brahm
diagnostica
berlin
germani
accord
manufactur
instruct
sensit
nmoll
neopterin
refer
level
healthi
control
set
nmoll
result
present
mean
ae
sd
plot
neopterin
concentr
versu
time
admiss
present
mean
ae
sem
mann
whitney
test
use
assess
statist
signific
differ
correl
analys
perform
calcul
spearman
rank
correl
coeffici
level
signific
set
p
neopterin
level
rais
earli
stage
df
patient
serum
neopterin
concentr
rais
df
patient
earli
first
day
onset
symptom
nmoll
reach
mean
concentr
ae
nmoll
mean
ae
sd
rang
nmoll
acut
sera
fig
mean
neopterin
concentr
healthi
blood
donor
ae
nmoll
mean
ae
sd
rang
nmoll
thu
mean
neopterin
concentr
df
patient
exceed
control
fold
p
mean
concentr
neopterin
df
patient
slightli
higher
patient
acut
measl
infect
ae
nmoll
nearli
threefold
higher
acut
influenza
sera
ae
nmoll
differ
group
statist
signific
p
mann
whitney
test
higher
neopterin
level
associ
longer
fever
period
analyz
clinic
signific
increas
neopterin
earli
stage
df
patient
compar
patient
neopterin
level
differ
day
day
onset
fever
period
higher
neopterin
concentr
patient
associ
longer
durat
fever
neopterin
concentr
determin
within
first
two
day
predict
length
fever
episod
develop
thereaft
fig
patient
longer
fever
period
also
appear
sever
cours
diseas
includ
higher
fever
longer
hospit
period
tabl
present
studi
show
increas
serum
neopterin
concentr
df
patient
earli
first
day
onset
symptom
also
signific
differ
neopterin
concentr
acut
df
sera
healthi
blood
donor
neopterin
concentr
found
higher
acut
df
sera
compar
acut
measl
sera
acut
influenza
sera
dengu
viru
primarili
infect
human
monocyt
macrophag
regardless
stage
cell
differenti
dengu
viru
infect
monocyt
macrophag
secret
multipl
innat
cytokin
chemokin
kinet
neopterin
concentr
base
df
patient
indic
earli
neopterin
elev
detect
earli
day
onset
symptom
quickli
reach
peak
level
day
onset
neopterin
concentr
maintain
high
level
day
onset
fals
neg
result
within
period
data
confirm
extend
result
earlier
pilot
studi
patient
dengu
viru
infect
observ
also
fit
well
data
obtain
viru
infect
hiv
rubella
also
ebola
agre
result
eg
experiment
infect
rhesu
macaqu
simian
immunodefici
viru
siv
data
avail
primarili
studi
infect
impli
predict
valu
neopterin
concentr
might
exist
also
patient
df
lower
neopterin
concentr
like
recov
other
notabl
behavior
neopterin
concentr
acut
df
patient
similar
sever
acut
respiratori
syndrom
sar
cytomegaloviru
cmv
rubella
infect
differ
consider
patient
anim
siv
infect
like
df
patient
sar
acut
cmv
rubella
infect
caus
sharp
increas
neopterin
concentr
follow
seroconvers
drop
neopterin
concentr
rang
healthi
control
higher
neopterin
concentr
df
patient
associ
longer
fever
period
thu
reflect
sever
inflamm
occur
patient
show
neopterin
earli
refer
indic
sever
df
use
neopterin
quantifi
sever
inflamm
df
patient
patient
receiv
proper
medic
treatment
earli
stage
thu
produc
good
recoveri
rate
contribut
consider
econom
gain
patient
hospit
serum
neopterin
exhibit
agedepend
sexdepend
neopterin
concentr
healthi
control
age
year
year
ae
nmoll
percentil
ae
nmoll
present
studi
neopterin
concentr
healthi
control
age
year
mean
ae
sd
ae
nmoll
compar
data
literatur
ae
nmoll
albeit
slightli
higher
patient
chronic
renal
failur
concentr
neopterin
serum
like
high
elev
longer
period
time
df
patient
separ
two
group
base
serum
neopterin
level
higher
group
lower
group
mean
valu
neopterin
test
blood
sampl
collect
day
onset
diseas
studi
cohort
b
p
thu
caution
must
taken
use
neopterin
screen
df
case
renal
insuffici
date
commerci
avail
biomark
test
approv
use
aid
assess
diagnosi
df
variou
report
scientif
literatur
describ
abil
variou
biomark
predict
identifi
df
vari
success
biomark
panel
approach
enhanc
diagnost
accuraci
particularli
panel
includ
protein
marker
associ
variou
compon
diseas
pathophysiolog
applic
new
biomark
studi
dengu
diagnosi
pathogenesi
repres
signific
challeng
futur
studi
requir
valid
refin
optim
serum
neopterin
cutoff
valu
prognosi
futur
work
address
relationship
neopterin
level
among
patient
df
dhfdss
effect
treatment
morbid
outcom
technolog
advanc
may
enhanc
use
neopterin
measur
acut
infect
present
use
neopterin
elisa
allow
result
avail
least
h
sampl
studi
report
neopterin
earli
marker
assess
sever
df
elev
neopterin
level
detect
earli
first
day
onset
symptom
data
suggest
neopterin
measur
could
serv
earli
predictor
futur
cours
dengu
viru
infect
